Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 701–741 of 741
Yu, Z., & Tao, W. (2026) · MEDS Chinese Medicine · doi:10.23977/medcm.2026.080102
“The pain and functional impairment caused by OP and its resulting fractures severely compromise patients' quality of life, establishing OP as a major chronic disease threatening the health of middle-aged and older adults [5].”
Sojobi, J. W., Yeesuf, J. O., Ajibola, A. M., Ajala, O. O., Ogunbiyi, O. O., Daramola, D. O., Ogunsanya, A. O., Odili, C. C., & Fayomi, O. S. I. (2026) · Next research. · doi:10.1016/j.nexres.2026.101468
Wenyang1, Z. Y. L. (2026) · International Journal of Frontiers in Medicine · doi:10.25236/ijfm.2026.080101
Dual therapy maximizes nerve growth and functional recovery of muscle and bonePreprint
Rabey, K. N., Senger, J. B., Khetarpal, N., Wang, B., Lin, Y.-H. S., Kwan‐Wong, T., Chan, K. M., & Webber, C. A. (2026) · Research Square · doi:10.21203/rs.3.rs-8835249/v1
Betancur, M. A. Q., & Betancur, A. M. Q. (2021) · Repositorio CES
Li, M., Wang, J., Ruan, H., Wang, Z., Wang, S., He, Y., & Zhang, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752252
Prevence sekundárních fraktur: multioborové konsenzuální stanovisko ke klinickým doporučením
Conley, R. B., Adib, G., Adler, R. A., Kristina, K. E., Ivy, A. M., Amenta, K. C., Robert, B. D., Brox, W. T., Emily, C. E., Chapman‐Novakofski, K., et al. (2020) · Clinical Osteology · doi:10.36290/clo.2020.002
Controversies in osteoporosis – are we treating bone density or preventing fractures?
Kraljević, I. (2026) · Liječnički vjesnik · doi:10.26800/lv-148-1-2-5
Jerczak, M., Przybył, F., Pluszyński, T., Piórkowska, I., Padula, N., Paczosa, K., Polewka, M., Polanska, A., & Piotrowski, K. (2026) · Quality in Sport · doi:10.12775/qs.2026.54.70412
Osteoporose: diagnóstico densitométrico do T ao Z
Szejnfeld, V. L. (2025) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2025.24.3.62-65
Modelo predictivo de fractura osteoporótica con Inteligencia Artificial
Sotos, J. M. (2026) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/84059
Desai, A., Khataniar, H., Habib, H., Hashash, J. G., Farraye, F. A., Regueiro, M. D., Long, M., & Kochhar, G. S. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08020-7
Mohseni, S., Khalagi, K., Amanollahi, A., Fahimfar, N., Sani, M. P., Nabipour, I., & Ostovar, A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01944-1
Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study
Harada, T., & Kosaka, S. (2026) · Journal of General and Family Medicine · doi:10.1002/jgf2.70126
Osteoporosis y metabolismo fosfocálcico
Ferrari, E. H., & Loudet, C. (2026) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata)
Feng, C., Shu, J., Li, Y., & Lin, Z. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1825374
“Nevertheless, most osteoporosis research has focused on women, leading to underestimation, underdiagnosis, and undertreatment in men (Rinonapoli et al., 2021; Qaseem et al., 2017).”
Qin, N., Gan, Y., Ouyang, J., Qin, J., Tang, Y., Wu, H., Wei, S., Wang, H., & Huang, J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349218
Regional data, global lessons: what the Asia–Pacific osteoporosis audit teaches the world
Chandran, M., Mitchell, P., Ebeling, P. R., Mithal, A., Halbout, P., HARVEY, N. A., & McCloskey, E. V. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08097-0
Literature Review: Glucocorticoid-Induced Osteoporosis (GIOP) Therapy Based on Current Evidence
Putri, A. A., Royani, I., & Hidayati, P. H. (2026) · Journal of Community Health Provision · doi:10.55885/jchp.v6i2.1023
“…vitamin D supplementation is commonly recommended to help maintain bone mineral density and reduce fracture risk, particularly in patients who require glucocorticoids for an extended period (Agrawal et al., 2025; Tang et al., 2007; Boonen et al., 2006; Jackson et al., 2006; Qaseem et al., 2017).”
Mohseni, S., Khalagi, K., Amanollahi, A., Fahimfar, N., Sani, M. P., Nabipour, I., & Ostovar, A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02004-4
A comprehensive evaluation of seven osteoporosis screening tools
Zhang, Y., Duan, Z., Liu, J., Tian, C., Ma, M., Huang, X., & Geng, B. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08118-y
“Machine learning, a core component of artificial intel-ligence-based big data analytics, can automatically construct analytical models and identify complex patterns without rigid statistical assumptions [76–78].”
Li, Q., Zhou, F., Zeng, S., Gao, Y., Shen, Q., Wu, Y., Ma, C., Lin, Y., Xiao, J., & Huang, K. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179350
Huang, Q., & Jian, Z. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1795616
“BMI was computed as weight (kg)/height (m) (Qaseem et al., 2017).”
Khoirunnisa, S. H., Rasyida, A., & Purniawan, A. (2026) · AIP conference proceedings · doi:10.1063/5.0338640
Wang, Z., Liu, G., Lai, F., Xiao, X., & Xu, S. (2026) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2026.103263
Su, Z., Liang, Z., Qiu, S., Jin, H., Jiang, Y., Zhao, J., Hu, X., Li, Y., Liu, Y., Cheng, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71341
Gkastaris, K. (2023) · Acta Orthopaedica Et Traumatologica Hellenica
Aydın, Ş. (2024) · Yildiz Technical University - AVESIS
Guan, X., Wang, X., Zhang, W., Li, J., Hou, Z., Hu, Z., & Sun, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1917386
Trends in risk of subsequent fracture and post-fracture treatment among post-menopausal US women
Hurwitz, K. E., Burke, C. A., Faller, R. W., Yu, Y., Curtis, J. R., Cosman, F., Lewiecki, E. M., McDermott, M., Kim, M., & Brunetti, V. C. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.09.027
Takigawa, M., Kotake, K., Tsuge, T., Saitsu, A., Isaji, Y., Kondo, S., Maruyama, T., & Yamamoto, N. (2026) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-026-01751-x
Tan, Z., Zeng, J., Huang, F., Gao, F., Hu, Y., Guo, L., Guo, P., & Chen, L. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179442
Quality of osteoporosis management guidelines produced in China: a systematic review
Liu, X., Ge, M., Wu, C., Shen, K., Yang, J., & Sun, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1907308
Shuai, C. H. E. N., Jin, J., Yuwen, H. U., Tian, N., Han, H., Ziqing, X. U., Lan, W. U., & Zhiwei, L. I. (2026) · PubMed Central · doi:10.19852/j.cnki.jtcm.2026.05.007
Screening for Osteoporosis in Men Over Fifty With No Fracture History
Jumah, M. A., Alharbi, R. M., Alsalhi, A. K., Almutairi, S. A., Algharbi, O. A., Tayeb, R. K., Alhulaili, H. A., Alharbi, K. S., Alnemer, N. S., Makki, A. M., et al. (2026) · Journal of Healthcare Sciences · doi:10.52533/johs.2026.60118
Ovarian insufficiency across the lifespan: Diagnosis, Monitoring and HRT controversies
Thelan, L. E., & Sarvaideo, J. L. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.126
OSTEOPOROSIS: A REVIEW FOR CHIROPRACTIC CLINICIANS
Cook, A., Moss, T., & Malaya, C. (2023) · Journal of Contemporary Chiropractic · doi:10.67681/001c.78097
Zheng, Y., Yan, J., Zhang, X., Cui, H., Wei, Z., Li, X., Wang, Q., & Zhong, B. (2023) · doi:10.3389/fendo.2023.1171781.s001
Gao, Y., Liu, X., Gu, Y., Song, D., Ding, M., Liao, L., Wang, J., Ni, J., & He, G. (2021) · doi:10.3389/fendo.2021.688269.s001
Li, Z., Fan, Y., Huang, C., Liu, Q., Huang, M., Chen, B., Peng, Z., Zhu, W., & Ding, B. (2022) · doi:10.3389/fcvm.2022.934598.s002
Wang, Y., Gao, X., Lv, J., Zeng, Y., Li, Q., Wang, L., Zhang, Y., Gao, W., & Wang, J. (2022) · doi:10.3389/fcimb.2022.827575.s009
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.